Search Results
Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation
Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations
Ibrutinib’s Efficacy in CLL Patients with Various Gene Mutations
Obinutuzumab, Ibrutinib, & Venetoclax in 17p / TP53 CLL - Dr. Stephan Stilgenbauer ASH 2022
CLL: Optimal approaches for patients with deletion 17p
Real-world analysis of the impact of del(17p) on ibrutinib efficacy in CLL
Real-World Support for Ibrutinib as a Treatment for High-Risk CLL
Evaluation 17p del CLL patients treated with ibrutinib: cross-study analysis of treatment outcomes
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
Outcomes of TP53-disrupted CLL patients treated with frontline ibrutinib
The definition of high-risk CLL
The importance of TP53 testing in CLL
